222 related articles for article (PubMed ID: 33305597)
1. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
Gharib KE
Future Oncol; 2021 Feb; 17(6):633-636. PubMed ID: 33305597
[No Abstract] [Full Text] [Related]
2. The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.
Zhang T; Hwang JK; George DJ; Pal SK
Cancer Treat Res Commun; 2020; 24():100183. PubMed ID: 32563923
[TBL] [Abstract][Full Text] [Related]
3. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges.
Voss MH; Motzer RJ
N Engl J Med; 2024 Apr; 390(15):1432-1433. PubMed ID: 38631007
[No Abstract] [Full Text] [Related]
6. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
7. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.
Gurram S; Al Harthy M; Ball MW
Discov Med; 2020; 29(158):191-199. PubMed ID: 33007194
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab after Failure of Prior Tyrosine Kinase Inhibitors.
Takemura K; Yuasa T; Fujiwara R; Ito M; Suzuki H; Yonese J; Koga F
J Urol; 2020 Dec; 204(6):1166-1172. PubMed ID: 32567459
[TBL] [Abstract][Full Text] [Related]
9. [Why have tyrosine kinase inhibitors failed in the adjuvant situation and do checkpoint inhibitors make more sense?].
Krege S
Urologe A; 2020 Feb; 59(2):149-154. PubMed ID: 32076796
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
Flaifel A; Xie W; Braun DA; Ficial M; Bakouny Z; Nassar AH; Jennings RB; Escudier B; George DJ; Motzer RJ; Morris MJ; Powles T; Wang E; Huang Y; Freeman GJ; Choueiri TK; Signoretti S
Clin Cancer Res; 2019 Oct; 25(20):6080-6088. PubMed ID: 31371341
[TBL] [Abstract][Full Text] [Related]
11. Strategies to overcome therapeutic resistance in renal cell carcinoma.
Siska PJ; Beckermann KE; Rathmell WK; Haake SM
Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
[TBL] [Abstract][Full Text] [Related]
12. Updates to the Management of Kidney Cancer.
Jonasch E
J Natl Compr Canc Netw; 2018 May; 16(5S):639-641. PubMed ID: 29784745
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
Narayan V; Puligandla M; Haas NB; Subramanian P; DiPaola RS; Uzzo R
J Urol; 2019 Jan; 201(1):62-68. PubMed ID: 30130544
[TBL] [Abstract][Full Text] [Related]
16. Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review.
Rizzo A; Mollica V; Dall'Olio FG; Ricci AD; Maggio I; Marchetti A; Rosellini M; Santoni M; Ardizzoni A; Massari F
Future Oncol; 2021 Jul; 17(20):2671-2681. PubMed ID: 33880963
[TBL] [Abstract][Full Text] [Related]
17. [Renal cell carcinoma: what is new in 2010?].
Tsaur I; Haferkamp A
Urologe A; 2011 Sep; 50 Suppl 1():216-8. PubMed ID: 21837489
[TBL] [Abstract][Full Text] [Related]
18. [Are immunotherapy and chemotherapy in metastatic renal cell cancer out?].
Schmitz-Dräger BJ
Urologe A; 1992 Jul; 31(4):213-4. PubMed ID: 1514204
[No Abstract] [Full Text] [Related]
19. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.
Pinato DJ; Fessas P; Sapisochin G; Marron TU
Hepatology; 2021 Jul; 74(1):483-490. PubMed ID: 33369758
[No Abstract] [Full Text] [Related]
20. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]